A Study for Adults With Plaque Psoriasis

Stopped The trial was terminated for several reasons, including complexities in development of LY2525623, but not because of safety concerns

Conditions

• Psoriasis

Interventions

• DRUG: LY2525623 Intravenous
• DRUG: LY2525623 Subcutaneous
• DRUG: Placebo Intravenous
• DRUG: Placebo Subcutaneous

Sponsor

Eli Lilly and Company